Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03827798 · ClinicalTrials.gov registry record · Phase 2

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

A Phase 2 study of Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals.

Active
Registry status
Phase 2
Development phase
248
Enrollment target
20
Study locations

NCT03827798 is a Phase 2 study of Hidradenitis Suppurativa that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 248 participants, below the 593-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03827798, a Phase 2 study of Hidradenitis Suppurativa, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
248 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to assess preliminary efficacy and safety of CFZ533/iscalimab (Cohort A), LYS006 (Cohort B), MAS825 (Cohort C), LOU064/remibrutinib (Cohort D) and VAY736/ianalumab (Cohort E) in patients with moderate to severe hidradenitis suppurativa and to determine if CFZ533, LYS006, MAS825, LOU064 and VAY736 have an adequate clinical profile for further clinical development.

Conditions Studied

Hidradenitis Suppurativa

Interventions

  • DRUG MAS825
  • DRUG CFZ533
  • DRUG Placebo to CFZ533
  • DRUG LYS006
  • DRUG Placebo to LYS006

Study Locations (20)

Other

  • Novartis Investigative Site - Graz
  • Novartis Investigative Site - Brussels
  • Novartis Investigative Site - Copenhagen
  • Novartis Investigative Site - Roskilde
  • Novartis Investigative Site - Antony
  • Novartis Investigative Site - Lyon
  • Novartis Investigative Site - Marseille
  • Novartis Investigative Site - Nice
  • Novartis Investigative Site - Reims
  • Novartis Investigative Site - Rouen
  • Novartis Investigative Site - Bochum

Florida

  • Olympian Clinical Research - Clearwater
  • Park Avenue Dermatology PA - Orange Park
  • University Of South Florida - Tampa

Georgia

  • Advanced Medical Research - Sandy Springs

Illinois

  • NorthShore University Health System - Evanston

Indiana

  • Dawes Fretzin Clinical Rea Group - Indianapolis

Pennsylvania

  • Penn State Milton S Hershey Medical Center - Hershey

South Carolina

  • Medical University of South Carolina MUSC - Charleston

Prague 1

  • Novartis Investigative Site - Prague

Trial Details

FieldValue
Enrollment Target 248 participants
Start Date 2019-02-27
Est. Completion 2026-12-11
Phase Phase 2

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03827798

The ClinicalTrials.gov registry entry for NCT03827798 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 593-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (58% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 5 interventions - of which MAS825 is the first listed.

NCT03827798 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT03827798 about?

NCT03827798 is a clinical study titled "Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa". The main purpose of this study is to assess preliminary efficacy and safety of CFZ533/iscalimab (Cohort A), LYS006 (Cohort B), MAS825 (Cohort C), LOU064/remibrutinib (Cohort D) and VAY736/ianalumab (Cohort E) in patients with moderate to severe hidradenitis suppurativa and to determine if CFZ533, LY...

What is the current status of trial NCT03827798?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 248 participants. The study started on 2019-02-27. Estimated completion is 2026-12-11.

What conditions does trial NCT03827798 study?

This clinical trial studies the following conditions: Hidradenitis Suppurativa.

What interventions are being tested in trial NCT03827798?

The interventions under investigation include: MAS825 (DRUG), CFZ533 (DRUG), Placebo to CFZ533 (DRUG), LYS006 (DRUG), Placebo to LYS006 (DRUG).

Who is sponsoring clinical trial NCT03827798?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03827798 being conducted?

This trial has 20 study locations across Florida, Georgia, Illinois, Indiana, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hidradenitis Suppurativa

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hidradenitis Suppurativa

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.